SUDEEPPHRM Share Price | Sudeep Pharma Ltd Stock Analysis & Recommendation

Q: Why is Sudeep Pharma Ltd falling/rising?

As of 15-Jun, Sudeep Pharma Ltd's stock price is rising, currently at Rs. 823.00, reflecting an increase of Rs. 73.5 or 9.81%. This upward movement is supported by several key factors. The stock has outperformed the benchmark Sensex, showing a 1-week return of +13.20% compared to the Sensex's +3.73%, and a 1-month return of +26.93% against the Sensex's +1.36%. Year-to-date, the stock has risen by +36.61%, while the Sensex has declined by -10.51%.Today, the stock reached a new 52-week and all-time high of Rs. 824.45, indicating strong investor interest. The stock has been on a consecutive gain streak for the last two days, with a total increase of 12.88% during this period. Additionally, the stock's performance today has outpaced its sector by 10.44%. Investor participation has also increased, with a delivery volume of 1.8 lacs on June 12, which is a significant rise of 59.63% compared to the 5-day average. Furthermore, Sudeep Pharma is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a strong upward trend. The company's financial health is bolstered by a low Debt to EBITDA ratio of 0.68 times and a high return on equity (ROE) of 0%, indicating efficient management and a strong ability to service debt. Positive quarterly results, including the highest net sales and profits recorded, further enhance investor confidence. Collectively, these factors contribute to the rising stock price of Sudeep Pharma Ltd.

Q: What does Sudeep Pharma do?

Overview: Sudeep Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.History: The incorporation year and any status changes are not provided. The latest quarterly results report net sales and profit for the period ending March 2026.Financial Snapshot: Most recent Net Sales: 182 Cr (Quarterly Results - Mar 2026) Most recent Net Profit: 49 Cr (Quarterly Results - Mar 2026) Market-cap value: INR 8,550 Cr (Small Cap)Key Metrics: P/E: 48.00 Industry P/E: 34 Dividend Yield: 0.00% Debt-Equity: 0.04 Return on Equity: 19.57% Price to Book: 9.47Contact Details: Registrar Address: Not available. Phone: N/A Email: N/A Website: N/A

Q: How big is Sudeep Pharma?

As of 10th June, Market Cap: Sudeep Pharma Ltd has a market capitalization of 8,550.00 Cr, classifying it as a Small Cap company.Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 642.27 Cr, while the sum of Net Profit for the same period is 172.90 Cr.Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 493.09 Cr, and Total Assets amount to 716.85 Cr.

Q: Who are the peers of the Sudeep Pharma?

Peers: The peers of Sudeep Pharma are Sanofi Consumer, P & G Health Ltd, Akums Drugs, Strides Pharma, Blue Jet Health, Supriya Lifesci., Sanofi India, SPARC, and FDC.Quality Snapshot: Excellent management risk is observed at Sanofi Consumer, P & G Health Ltd, and Sanofi India, while Good management risk is found at Blue Jet Health and Supriya Lifesci., and the rest have Average management risk. All peers exhibit Below Average growth except for SPARC, which has Excellent growth, while Akums Drugs, Strides Pharma, Blue Jet Health, Supriya Lifesci., Sanofi India, and FDC show Below Average growth. Excellent capital structure is noted at Sanofi Consumer, P & G Health Ltd, Blue Jet Health, Supriya Lifesci., and FDC, while Good capital structure is found at Akums Drugs, Average capital structure is seen at Strides Pharma and SPARC, and the rest have Below Average capital structure.Return Snapshot: Supriya Lifesci. has the highest 1-year return at 42.25%, while Sanofi India has the lowest at -48.76%, with Sudeep Pharma's 1-year return being N/A. Additionally, Sanofi India and FDC have negative six-month returns.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

16.35 lacs (207.72%) Volume

Shareholding (Mar 2026)

FII

1.55%

Held by 13 FIIs

DII

18.11%

Held by 10 DIIs

Promoter

76.15%

Why is Sudeep Pharma Ltd falling/rising?

16-Jun-2026

As of 15-Jun, Sudeep Pharma Ltd's stock price is rising to Rs. 823.00, up 9.81%, driven by strong performance metrics, including significant returns compared to the Sensex, a new all-time high, and increased investor participation, alongside solid financial health indicators.

View full answer

Which are the latest news on Sudeep Pharma?

15-Jun-2026

Sudeep Pharma Gains 1.82%: 4 Key Factors Driving the Week’s Momentum
Sudeep Pharma Ltd Reports Record Quarterly Performance Amid Flat Financial Trend

What does Sudeep Pharma do?

11-Jun-2026

Sudeep Pharma Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 182 Cr and a net profit of 49 Cr for the quarter ending March 2026. Key metrics include a P/E ratio of 48.00 and a market cap of INR 8,550 Cr.

View full answer

How big is Sudeep Pharma?

11-Jun-2026

As of 10th June, Sudeep Pharma Ltd has a market capitalization of 8,550.00 Cr, with recent net sales of 642.27 Cr and net profit of 172.90 Cr over the last four quarters.

View full answer

Who are the peers of the Sudeep Pharma?

11-Jun-2026

Sudeep Pharma's peers include Sanofi Consumer, P & G Health Ltd, Akums Drugs, Strides Pharma, Blue Jet Health, Supriya Lifesci., Sanofi India, SPARC, and FDC. Most peers show Below Average growth and management risk, with SPARC exhibiting Excellent growth, while Supriya Lifesci. has the highest 1-year return at 42.25% and Sanofi India the lowest at -48.76%.

View full answer

Should I buy, sell or hold Sudeep Pharma Ltd?

23-May-2026

When is the next results date for Sudeep Pharma Ltd?

15-May-2026

The next results date for Sudeep Pharma Ltd is 21 May 2026.

View full answer

Compare Sudeep Pharma with Similar Stocks

Blue Jet Health Supriya Lifesci.Strides Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 0%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.68 times

Poor long term growth as Operating profit has grown by an annual rate 0% of over the last 5 years

Positive results in Mar 26

With ROE of 19.6, it has a Very Expensive valuation with a 10.5 Price to Book Value

Majority shareholders : Promoters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 8,635 Cr (Small Cap)

P/E

54.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.04

Return on Equity

19.57%

Price to Book

9.62

Revenue and Profits:

Net Sales:

182 Cr

(Quarterly Results - Mar 2026)

Net Profit:

49 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

38.55%

6 Months

23.0%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Sudeep Pharma for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Broad-Based Technical Strength Lifts Sudeep Pharma Ltd to 52-Week High of Rs 820.7

Surging to an intraday peak of Rs 820.7 on 15 Jun 2026, Sudeep Pharma Ltd has marked a fresh 52-week high, propelled by a confluence of robust technical signals and sustained price momentum that outpaced its sector peers.

Read full news article

Sudeep Pharma Ltd Hits All-Time High of Rs 824.45 as Momentum Accelerates

Extending its recent rally, Sudeep Pharma Ltd surged 10.00% on 15 Jun 2026 to close at Rs 824.45, marking a fresh all-time high. This move outpaced the Sensex gain of 1.29% and reinforced the stock’s strong short-term momentum across multiple timeframes.

Read full news article

Sudeep Pharma Ltd Surges 8.99% to Day's High of Rs 796.55 — Outperforms Sector by 6.86 Percentage Points

The Sensex gained 1.27% on 15 Jun 2026, yet Sudeep Pharma Ltd outpaced the broader market with an 8.99% surge, reaching an intraday high of Rs 796.55. This 6.86-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Read full news article

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

28-May-2026 | Source : BSE

Submission of Earnings Call Transcript for Q4 FY26.

Compliances-Reg.24(A)-Annual Secretarial Compliance

27-May-2026 | Source : BSE

Submission of Annual Secretarial Compliance Report for FY 2025-26

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

23-May-2026 | Source : BSE

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 as amended from time to time we herewith submit the participation of Company Officials in various Investor Conferences in Mumbai as annexed.

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

33.98

Debt to EBITDA (avg)

0.72

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.65

Tax Ratio

23.58%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

19.67%

ROCE (avg)

24.88%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

10.50

EV to EBIT

44.95

EV to EBITDA

41.95

EV to Capital Employed

10.13

EV to Sales

14.49

PEG Ratio

Dividend Yield

ROCE (Latest)

22.53%

ROE (Latest)

19.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

RSI

No Signal

Bollinger Bands

Bullish

KST

Dow Theory

Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 14 Schemes (6.19%)

FIIs

Held by 13 FIIs (1.55%)

Promoter with highest holding

Riva Resources Private Limited (40.35%)

Highest Public shareholder

Nuvama Crossover Opportunities Fund - Series Iii (3.42%)

Individual Investors Holdings

3.11%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -11.20% vs 2.73% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -4.09% vs -9.65% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "80.17",
          "val2": "90.28",
          "chgp": "-11.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "28.89",
          "val2": "29.61",
          "chgp": "-2.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.97",
          "val2": "0.63",
          "chgp": "212.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "25.77",
          "val2": "26.87",
          "chgp": "-4.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.04%",
          "val2": "32.80%",
          "chgp": "3.24%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "168.06",
          "val2": "168.40",
          "chgp": "-0.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "61.27",
          "val2": "60.03",
          "chgp": "2.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.47",
          "val2": "1.99",
          "chgp": "74.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "54.95",
          "val2": "41.98",
          "chgp": "30.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.46%",
          "val2": "35.65%",
          "chgp": "0.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "258.34",
          "val2": "251.88",
          "chgp": "2.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "90.88",
          "val2": "86.49",
          "chgp": "5.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "3.24",
          "chgp": "26.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "81.82",
          "val2": "62.61",
          "chgp": "30.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "35.18%",
          "val2": "34.34%",
          "chgp": "0.84%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "642.26",
          "val2": "502.00",
          "chgp": "27.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "221.91",
          "val2": "189.95",
          "chgp": "16.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "5.85",
          "chgp": "29.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "172.89",
          "val2": "138.73",
          "chgp": "24.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.55%",
          "val2": "37.84%",
          "chgp": "-3.29%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

80.17

90.28

-11.20%

Operating Profit (PBDIT) excl Other Income

28.89

29.61

-2.43%

Interest

1.97

0.63

212.70%

Exceptional Items

0.00

Standalone Net Profit

25.77

26.87

-4.09%

Operating Profit Margin (Excl OI)

36.04%

32.80%

3.24%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -11.20% vs 2.73% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is -4.09% vs -9.65% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

168.06

168.40

-0.20%

Operating Profit (PBDIT) excl Other Income

61.27

60.03

2.07%

Interest

3.47

1.99

74.37%

Exceptional Items

0.00

Standalone Net Profit

54.95

41.98

30.90%

Operating Profit Margin (Excl OI)

36.46%

35.65%

0.81%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

258.34

251.88

2.56%

Operating Profit (PBDIT) excl Other Income

90.88

86.49

5.08%

Interest

4.10

3.24

26.54%

Exceptional Items

0.00

Standalone Net Profit

81.82

62.61

30.68%

Operating Profit Margin (Excl OI)

35.18%

34.34%

0.84%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

642.26

502.00

27.94%

Operating Profit (PBDIT) excl Other Income

221.91

189.95

16.83%

Interest

7.60

5.85

29.91%

Exceptional Items

0.00

Consolidate Net Profit

172.89

138.73

24.62%

Operating Profit Margin (Excl OI)

34.55%

37.84%

-3.29%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025

All Annual Results

Company CV

About Sudeep Pharma Ltd

Sudeep Pharma Ltd

Small Cap

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available